These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 2693361)

  • 1. Cefotaxime in urinary tract infections.
    Naber KG
    Infection; 1989; 17(6):425-8. PubMed ID: 2693361
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics, in-vitro activity, therapeutic efficacy and clinical safety of aztreonam vs. cefotaxime in the treatment of complicated urinary tract infections.
    Naber KG; Dette GA; Kees F; Knothe H; Grobecker H
    J Antimicrob Chemother; 1986 Apr; 17(4):517-27. PubMed ID: 3710959
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of serious urological infections with cefotaxime compared to ampicillin plus netilmicin.
    Rasmussen D; Bremmelgaard A; Rasmussen F; Thorup J
    Dan Med Bull; 1986 Feb; 33(1):49-51. PubMed ID: 3948539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cefotaxime therapy of serious infections with multiresistant gram-negative bacilli.
    Clumeck N; van Laethem Y; Vanhoof R; George C; Rapin M; Butzler JP
    Scand J Infect Dis; 1982; 14(1):57-60. PubMed ID: 6280269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cefotaxime and cefazolin in the treatment of complicated urinary tract infections: a comparative study.
    Madsen PO; Iversen P
    Clin Ther; 1981; 4(1):7-11. PubMed ID: 6268298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative in vitro activity of cefditoren and other antimicrobials against Enterobacteriaceae causing community-acquired uncomplicated urinary tract infections in women: a Spanish nationwide multicenter study.
    Cuevas O; Cercenado E; Gimeno M; Marín M; Coronel P; Bouza E;
    Diagn Microbiol Infect Dis; 2010 Jul; 67(3):251-60. PubMed ID: 20542206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Cefixime in urinary tract infections. (Specific studies and literature review)].
    Naber KG
    Infection; 1990; 18 Suppl 3():S132-9. PubMed ID: 2079373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ceftizoxime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
    Richards DM; Heel RC
    Drugs; 1985 Apr; 29(4):281-329. PubMed ID: 3888599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of urinary tract infections with cefotaxime: noncomparative and prospective comparative trials.
    Madsen PO
    Rev Infect Dis; 1982; 4 Suppl():S416-20. PubMed ID: 6294793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cefotaxime in the treatment of urinary tract infections.
    Porpaczy P
    J Antimicrob Chemother; 1984 Sep; 14 Suppl B():311-5. PubMed ID: 6094458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transferable enzymatic resistance to third-generation cephalosporins during nosocomial outbreak of multiresistant Klebsiella pneumoniae.
    Brun-Buisson C; Legrand P; Philippon A; Montravers F; Ansquer M; Duval J
    Lancet; 1987 Aug; 2(8554):302-6. PubMed ID: 2886766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Role of cefotaxime in the treatment of urinary tract infections from the viewpoint of the urologist].
    Porpaczy P
    Wien Klin Wochenschr Suppl; 1983; 142():24-6. PubMed ID: 6316670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Cefotaxime in the treatment of severe infections due to multiresistant Gram-negative bacilli (author's transl)].
    Clumeck N; Van Laethem Y; Vanhoof R; Jaspar N; George G; Rapin M; Butzler JP
    Nouv Presse Med; 1981 Feb; 10(8):622-4. PubMed ID: 6259606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Studies of susceptibility to antibiotics in strains of E. coli isolated from urine in the years 1986-1990].
    Szeniawska A; Jasińska B; Mazur E; Ligeza J; Fota-Markowska H; Kunkiewicz A; Niedźwiadek J
    Ann Univ Mariae Curie Sklodowska Med; 1992; 47():127-31. PubMed ID: 1365783
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changing pattern of antimicrobial susceptibility of organisms causing community acquired urinary tract infections.
    Farooqi BJ; Shareeq F; Rizvi QK; Qureshi HS; Ashfaq MK
    J Pak Med Assoc; 2000 Nov; 50(11):369-73. PubMed ID: 11126812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cefotaxime. A review of its antibacterial activity, pharmacological properties and therapeutic use.
    Carmine AA; Brogden RN; Heel RC; Speight TM; Avery GS
    Drugs; 1983 Mar; 25(3):223-89. PubMed ID: 6303743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cefixime in the treatment of respiratory and urinary tract infections.
    Ludwig E
    Chemotherapy; 1998 Sep; 44 Suppl 1():31-4. PubMed ID: 9797422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Comparative study of the in vitro activity of 5 new antibiotics on strains isolated from urinary infections].
    Salvo S; Falcidia A; Mirone L
    Minerva Med; 1987 Jan; 78(2):71-7. PubMed ID: 3543744
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cefotaxime for the treatment of gram-positive urinary tract infection.
    Piccinno A; Pagliarulo A
    Infection; 1985; 13 Suppl 1():S100-2. PubMed ID: 4055038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of ceftriaxone versus cefotaxime for childhood upper urinary tract infections.
    Bakkaloglu A; Saatci U; Soylemezoglu O; Ozen S; Topaloglu R; Besbas N; Saatci I
    J Chemother; 1996 Feb; 8(1):59-62. PubMed ID: 8835111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.